Rationale and design for the detection and neurological impact of cerebrovascular events in non-cardiac surgery patients cohort evaluation (NeuroVISION) study: a prospective international cohort study

Marko Mrkobrada, Matthew T V Chan, David Cowan, Jessica Spence, Douglas Campbell, Chew Yin Wang, David Torres, German Malaga, Robert D Sanders, Carl Brown, Alben Sigamani, Wojciech Szczeklik, Adam Andrew Dmytriw, Ronit Agid, Eric E Smith, Michael D Hill, Manas Sharma, Scott Tsai, Tony Gin, Pui San Loh, Norlisah Ramli, Yee Lein Siow, Timothy G Short, Ellen Waymouth, Jonathan Kumar, Monidipa Dasgupta, John M Murkin, Maite Fuentes, Victor Ortiz-Soriano, Heidi Lindroth, Sara Simpson, Daniel Sessler, P J Devereaux

ABSTRACT

Objectives Covert stroke after non-cardiac surgery may have substantial impact on duration and quality of life. In non-surgical patients, covert stroke is more common than overt stroke and is associated with an increased risk of cognitive decline and dementia. Little is known about covert stroke after non-cardiac surgery. NeuroVISION is a multicentre, international, prospective cohort study that will characterise the association between perioperative acute covert stroke and postoperative cognitive function.

Setting and participants We are recruiting study participants from 12 tertiary care hospitals in 10 countries on 5 continents.

Participants We are enrolling patients ≥65 years of age, requiring hospital admission after non-cardiac surgery, who have an anticipated length of hospital stay of at least 2 days after elective non-cardiac surgery that occurs under general or neuraxial anaesthesia.

Primary and secondary outcome measures Patients are recruited before elective non-cardiac surgery, and their cognitive function is measured using the Montreal Cognitive Assessment (MoCA) instrument. After surgery, a brain MRI study is performed between postoperative days 2 and 9 to determine the presence of acute brain infarction. One year after surgery, the MoCA is used to assess postoperative cognitive function. Physicians and patients are blinded to the MRI study results until after the last patient follow-up visit to reduce outcome ascertainment bias. We will undertake a multivariable logistic regression analysis in which the dependent variable is the change in cognitive function 1 year after surgery, and the independent variables are acute perioperative covert stroke as well as other clinical variables that are associated with cognitive dysfunction.

Conclusions The NeuroVISION study will characterise the epidemiology of covert stroke and its clinical consequences. This will be the largest and the most comprehensive study of perioperative stroke after non-cardiac surgery.

Trial registration number NCT01980511; Pre-results.

INTRODUCTION

Worldwide, 200 million adults have non-cardiac surgery requiring hospital admission annually. Non-cardiac surgery provides
substantial benefit to most patients; however, it is associated with major vascular complications including myocardial infarction, cardiac arrest, stroke and death. Although only a small proportion of patients will suffer a clinically overt perioperative stroke (~0.5%), these events often have a devastating effect on patients’ quality and duration of life. It is likely that there are many more covert than overt strokes, but the incidence of covert brain infarcts after non-cardiac surgery, and their implications for patients and families remain unknown.

Perioperative overt stroke
The true incidence of overt stroke after non-cardiac surgery remains unknown, and the estimates of the risk of stroke in the current literature vary from 0.2% to 4.3%. Stroke and postoperative cognitive dysfunction are of utmost concern to patients. A study of 1216 patients identified common fears when facing elective knee surgery, and found that the largest proportion of participants were ‘very concerned’ about perioperative ‘brain damage’ (19%, 234/1216), followed by ‘memory loss’ (17%, 210/1216). In contrast, only 12% (147/1216) were very concerned about death in the perioperative period.

In the Perioperative Ischemic Evaluation (POISE) Trial (international randomised trial of 8351 patients from 190 centres in 23 countries), stroke carried a high degree of morbidity and mortality. Among the 0.7% of patients who suffered a stroke, 32% died within 30 days and, of the survivors, 58% were left with major disability. In comparison, a meta-analysis of patient-level data from 1384 participants allocated to the placebo group of six large studies has evaluated the prevalence of covert stroke compared with stroke in the general population of older adults, but only a few small studies have evaluated the frequency of covert stroke in the perioperative setting after cardiac and carotid artery surgery, but not after non-cardiac surgery.

No study has examined the association of covert stroke with cognitive decline, as well as impairments in activities of daily living.

OBJECTIVES OF THE NEUROVISION STUDY
The NeuroVISION study aims to characterise the incidence, impact and risk factors of covert stroke in adults undergoing non-cardiac surgery. We will do this using a postoperative MRI study of the brain completed 2–9 days after surgery and follow-up assessment of neurocognitive function.

Primary outcome
The primary outcome is postoperative cognitive dysfunction, defined as a decrease of two or more points on the Montreal Cognitive Assessment (MoCA) scale from preoperative baseline to 1-year follow-up. We hypothesise that perioperative covert stroke is associated with cognitive dysfunction 1 year after surgery. We believe that cognitive assessment at 1 year after surgery informs the long-term impact of covert stroke, while cognitive assessments performed sooner after surgery may be affected by postoperative changes (eg, incisional pain, analgesics and surgery-related functional limitations).

The National Institute of Neurological Disorders and Stroke (NINDS) has coined the term ‘vascular cognitive impairment’ (VCI) for neurological dysfunction that is caused by, or associated with vascular factors. They have recommended the MoCA instrument as a tool for neurocognitive testing of patients with suspected VCI, and MoCA has shown good correlation when compared with the full 60 min NINDS VCI Battery neuropsychological assessment.

MoCA is used extensively in the assessment of cognitive function after stroke and cerebrovascular disease. It is superior to the Mini-Mental State Examination (MMSE) in assessments of language skills, visual-spatial and executive function, and in the diagnosis of cognitive dysfunction after stroke. MoCA assesses multiple cognitive domains, and it provides a thorough assessment of the impact of perioperative covert brain infarction. The MoCA instrument is more sensitive than the MMSE, and has a minimal ceiling effect. We will exclude patients with a history of dementia, thereby minimising the risk of floor effect with respect to the change in cognitive score.

Cognitive decline due to the ageing process is associated with lower MoCA scores. Previous studies have shown a decline of 1.4–2.2 points on the MoCA score for every additional 10 years of age in patients 65 years of age and older. It can be interpreted that a two-point difference in the MoCA score represents 10 years of brain ageing, and this would be relevant to patients and their caregivers. A change of two points on the MoCA score has been used as a cut-off for significant cognitive decline in published studies.
METHODS

Study design

The NeuroVISION Study is a multicentre, prospective cohort study being conducted in 12 tertiary hospitals from 10 countries on 5 continents.

Study population

We are enrolling patients ≥65 years of age, requiring hospital admission after non-cardiac surgery, and have an anticipated length of hospital stay of at least 2 days after elective non-cardiac surgery that occurs under general or neuraxial anaesthesia. We obtain consent for participation in NeuroVISION from the patients before surgery.

Patients who have a contraindication to MRI scanning (eg, implanted devices not safe for MRI studies, claustrophobia), patients who are unable or unwilling to attend the follow-up appointments, patients who have a documented history of dementia as diagnosed by a physician or who reside in a nursing home, and patients undergoing carotid artery surgery or intracranial surgery are excluded from the study. We are also excluding patients who are not able to complete neurocognitive testing due to language, vision or hearing impairment, those who are not able to communicate with the research staff due to language barriers, patients who do not consent to participate, and those who were previously enrolled in the NeuroVISION Study.

Patient and public involvement

Patients and public were not involved in the development of the research question or the design of the study. Study results will be disseminated by publication in a medical journal, and poster presentation at a medical conference.

Sampling strategy

In the NeuroVISION Pilot Study,23 there were approximately 15–30 eligible patients per centre each week, but due to limitations on the availability of the MRI scanners, each centre could only recruit up to two patients per week. Because of the disparity between the number of eligible patients and the MRI capacity, we are employing a sampling strategy to ensure proportionate representation of patients that reflects the overall surgical population by randomly assigning the days of recruitment for specific surgery subtypes, proportional to the prevalence of surgery type at each local centre.

Clinical data collection

Research personnel approach all patients who fulfil the eligibility criteria to obtain informed consent before the day of surgery. After obtaining written informed consent from eligible patients or their legal decision-makers, research personnel administer the MoCA questionnaire, the Digit-Symbol Substitution Test (DSST)24 and the Trail-Making Test Part B (TMT-B)25 to assess baseline cognitive function. They also administer the Lawton Instrumental Activities of Daily Living (iADL) Scale,26 modified Rankin Scale,27 Geriatric Depression Scale (GDS)28 and the EQ-5D questionnaire29 to assess physical function, mood and health-related quality of life at baseline. The research personnel interview patients and review their charts to obtain baseline clinical information including patient demographics (age, sex and ethnicity), medical history (eg, prior cerebrovascular disease, other vascular risk factors and adverse cardiac events, venous thromboembolic disease, depression and anxiety, and respiratory diseases) and medication use prior to surgery (eg, cardiac medications, antiplatelet agents and anticoagulants, narcotics and other psychoactive medications).

Research personnel follow patients until hospital discharge. The patients are screened for delirium two times per day during the first 72 hours after surgery. Assessment for delirium is performed using the confusion assessment method.30 Study personnel also collect detailed haemodynamic data as well as predefined clinical outcomes (overt stroke or transient ischaemic attack (TIA), adverse vascular events, bleeding, infection and kidney injury) occurring during the hospital stay.

Research personnel contact patients by phone 30 days after surgery. They collect data regarding predefined clinical outcomes (overt stroke or TIA, adverse vascular events, bleeding, infection and kidney injury), and administer the Lawton iADL Scale, Modified Rankin Scale, GDS and EQ-5D questionnaires. At 1 year after surgery, research personnel assess the patients in person. They collect data regarding predefined clinical outcomes (overt stroke or TIA, adverse vascular events, incident dementia, incident depression or anxiety), and administer the MoCA, DSST, TMT, Lawton iADL Scale, Modified Rankin Scale, GDS and EQ-5D questionnaires.

Detection of acute stroke in the perioperative setting

Acute postoperative covert stroke is detected using an MRI study of the brain performed between postoperative days 2 and 9, as early as the patient can tolerate the procedure. The majority of the covert strokes occurred by postoperative day 2 in previous large perioperative trials,2 31 and we have chosen the timing of MRI on the basis of this experience, as well as the similarity to prior protocols.32–34

The MRI sequences consist of axial fluid-attenuated inversion recover (FLAIR), gradient echo (GRE), T2 and diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping. MRI sequences are performed according to the local standard of care with a minimum 1.5 T MRI machine, and a slice thickness of 3–5 mm, with no gap. The DWI sequence has the ability to detect acute cerebral ischaemia that has occurred during the time window of minutes before the study up to approximately 10 days prior.35 Therefore, it is not necessary to obtain a preoperative MRI scan in order to detect new covert brain infarctions. DWI MRI is very sensitive for the diagnosis of cerebral ischaemia, approaching 100%.36,37 Where relevant, we use the ADC maps to aid us in determining whether a DWI lesion is new or old: a component of the DWI signal comes from T2 prolongation, and discriminating new from chronic lesions is...
Patient identifiers are removed, and MRI images are electronically transferred via a secure encrypted connection to the central imaging core laboratory. Two separate teams of clinicians with expertise in neuroradiology independently assess the studies in duplicate and provide a consensus interpretation regarding the presence of imaging lesions that represent acute perioperative cerebral ischaemia and chronic ischaemic findings, haemorrhages and white matter hyperintensities, defined according to consensus criteria. Any disagreements are resolved by consensus. These clinicians are blinded to the baseline characteristics and clinical outcomes.

Ethics and blinding of the MRI study results

The results of the MRI scans are blinded until after the last patient follow-up visit. However, the MRI scans are reviewed immediately after image acquisition for clinically relevant non-ischaemic incidental findings. If identified, these findings are immediately reported to the study team and the attending physician involved in the care of the patient, and recorded in the study database. This protocol is in keeping with the Canadian Tri-Council policy defined in ‘Ethical Conduct for Research Involving Humans’, as well as previously published literature. The research ethics board at each site approved the protocol prior to patient recruitment.

We blind healthcare providers and patients to the MRI results for the following reasons: (1) blinding of study results eliminates potential bias in the ascertainment of study outcomes; (2) this study is not a part of the standard of care in the postoperative period; (3) the implications of acute covert stroke in the perioperative period are unknown and any management decisions on the basis of the MRI study would not be based on evidence but could positively or negatively impact outcomes; (4) any incidental finding, such as a tumour, is communicated to the attending physicians, as soon as the scan is read and (5) the research MRI study will be available for future comparisons if required for clinical care after the completion of the study.

Sample size

Our sample size calculation was based on our primary objective, the proportion of patients with a decrease of two or more points on the MoCA scale from preoperative baseline to 1-year follow-up. We will undertake a multivariable analysis to determine if postoperative covert stroke is associated with the incidence of postoperative cognitive dysfunction as measured by the MoCA, at 1 year after surgery (ie, the dependent variable). The International Study of Postoperative Cognitive Dysfunction 1 of postoperative cognitive dysfunction in patients aged 60 years or older demonstrated a 9.9% incidence of postoperative cognitive dysfunction 3 months after surgery (95% CI 8.1% to 12.0%), while a subsequent study showed an incidence of 12.7% in patients over the age of 60 (95% CI 8.9% to 16.4%). Increasing age was associated with an increased risk of cognitive dysfunction (5.7% in patients under 60 vs 12.7% in patients 60 years or older, p<0.001). Our study recruits patients who are at least 65 years old, and the risk of cognitive dysfunction may be even greater in this group. From non-operative literature, we expect that covert stroke will be associated with at least a twofold increase in the risk of cognitive dysfunction.

A sample size of 900 patients would allow us to detect a minimum OR of 1.89 for the risk of cognitive dysfunction after a covert perioperative stroke, with 80% power and a two-sided alpha of 0.05, assuming a 30% incidence of postoperative cognitive dysfunction and a 10% incidence of postoperative covert brain infarction. A sample size of 1000 patients would allow us to detect a minimum OR of 1.93 for the risk of cognitive dysfunction after a covert perioperative stroke, with 80% power and a two-sided alpha of 0.05, assuming a 20% incidence of postoperative cognitive dysfunction and a 10% incidence of postoperative covert brain infarction. A sample size of 1100 patients would allow us to detect a minimum OR of 2.17 assuming a 10% incidence of postoperative cognitive dysfunction and a 10% incidence of covert stroke, and would allow us to detect a minimum OR of 2.18 assuming a 30% incidence of postoperative cognitive dysfunction and a 5% incidence of covert stroke (see table 1).

Analysis plan for primary objective

Our primary objective is to characterise the impact of postoperative covert stroke on neurocognitive function 1 year after elective non-cardiac surgery. We will undertake a multivariable logistic regression analysis to develop a model in which the dependent variable is a decrease in the MoCA score of ≥2, 1 year after surgery compared with the baseline measurement. The independent variables

| Incidence of postoperative cognitive dysfunction | Incidence of covert stroke | Sample size (no of patients) | Sample size (no of patients) | Sample size (no of patients) |
|-----------------------------------------------|---------------------------|------------------------------|------------------------------|------------------------------|
|                                               | 5%                        | 900 1000 1100                | 900 1000 1100                | 900 1000 1100                |
|                                               | 10%                       | 2.96 2.83 2.72               | 2.49 2.39 2.31               | 2.36 2.26 2.18               |
|                                               | 10%                       | 2.32 2.24 2.17               | 1.99 1.93 1.88               | 1.89 1.83 1.78               |
are acute covert stroke in the perioperative setting (we will exclude patients who suffer an acute clinically symptomatic stroke in the time period between surgery and the MRI study, but expect this event to be very infrequent); history of stroke, coronary artery disease or peripheral vascular disease; depression; age; sex; baseline neurocognitive function as measured by MoCA; baseline physical impairment as measured by the Lawton scale; discontinuation of opioid or benzodiazepine medication; initiation of cholinesterase inhibitor and surgery type.

For all regression models, we will report the ORs, 95% CIs and associated p values. For all tests, we will use a two-sided alpha <0.05 level of significance. Examination of residuals will provide an assessment of model assumptions for regression analyses. Goodness of fit for the models will be assessed using appropriate Hosmer-Lemeshow tests. For multivariable regression analysis, we will assess for multicollinearity (correlations among predictor variables) using the variance inflation factor (VIF), which measures the extent to which the variance of the model coefficients is inflated (because of the correlation of the variable with other predictor variables) if that variable is included in the model. We will consider variables with VIF >10 collinear, and if this occurs, we will exclude one of the collinear variables from the analysis.

Approach to missing data

Even small proportions of missing data can bias study results, and cognitive decline may increase the risk of loss to follow-up and the risk of incomplete cognitive assessment. This may introduce systematic bias in the study analysis. It is possible to counteract this bias if the reason for missing data is known.43 44 We are collecting the reasons for missing data, and will use a method of evidence-informed data imputation to minimise systematic bias from incomplete cognitive assessments (see table 2).

CONCLUSION

Non-cardiac surgery is common, but despite evidence that perioperative brain damage and cognitive dysfunction is a major concern to patients undergoing elective surgery, there are limited data regarding the epidemiology of cerebral ischaemia during this period. If the non-cardiac surgery setting is similar to the non-operative and cardiac surgery evidence regarding covert stroke, upwards of 10 million adults worldwide may suffer perioperative covert brain infarctions. The NeuroVISION study will characterise the epidemiology of covert stroke and its clinical consequences. This is the largest study of perioperative covert stroke after non-cardiac surgery and will provide important insights for the millions of elderly adults undergoing non-cardiac surgery annually.

Table 2 Evidence-informed data imputation of missing data for cognitive assessments

| Probability of cognitive decline | Reported reasons for missing data | Data imputation | Missing data classification |
|----------------------------------|----------------------------------|-----------------|-----------------------------|
| Confirmed                        | New diagnosis of dementia        | Multiple imputations centred at the average MoCA score change for patients with new diagnosis of dementia, mild cognitive impairment or those started on medication to treat cognitive impairment. | Informative missing |
|                                  | New diagnosis of mild cognitive impairment |                    |                             |
|                                  | Started a medication to treat cognitive impairment (acetyl cholinesterase inhibitor, NMDA-receptor antagonist) |                    |                             |
| Probable                         | New diagnosis of stroke          | Multiple imputations centred at the average MoCA score change for those with MRI finding of old stroke or old cerebral small vessel disease |                             |
|                                  | Cardiovascular death             |                    |                             |
|                                  | Impairment on other related scale: decreased iADL (Lawton), depression (GDS) |                    |                             |
|                                  | Admission to long-term care facility or similar institution |                    |                             |
|                                  | Significant cognitive impairment reported by family or caregiver |                    |                             |
| Unlikely                         | Refusal or missed, but reported well | Multiple imputations centred at zero change in MoCA value |                             |
| Unknown                          | Lost to follow-up (likely <1%)   | Imputed directly through mixed model | Missing at random |

GDS, Geriatric Depression Scale; iADL, Lawton Instrumental Activities of Daily Living; MoCA, Montreal Cognitive Assessment; NMDA, N-methyl-D-aspartate.

Author affiliations

1University of Western Ontario, London, Ontario, Canada
2Chinese University of Hong Kong, Hong Kong, China
3McMaster University, Hamilton, Ontario, Canada
4Auckland City Hospital, Auckland, New Zealand
5University Malaya, Kuala Lumpur, Malaysia
6Clinica Santa Maria, Universidad de Los Andes, Santiago, Chile
7University Peruana Cayetano Heredia, Lima, Peru
8University of Wisconsin, Madison, Wisconsin, USA
9University of British Columbia, Vancouver, British Columbia, Canada
10Narayana Health, Bangalore, Karnataka, India
11Jagiellonian University Medical College, Krakow, Poland
12University of Toronto, Toronto, Ontario, Canada
13University of Calgary, Calgary, Alberta, Canada

Mrkobrada M, et al. BMJ Open 2018;8:e021521. doi:10.1136/bmjopen-2018-021521
4. Popa AS, Rabinstein AA, Huddleston PM, 3. Larsen SF, Zaric D, Boysen G. Postoperative cerebrovascular 6. references

14 Hamilton Health Sciences, Hamilton, Ontario, Canada 14 Cleveland Clinic, Cleveland, Ohio, USA

Acknowledgements Thanks to Drs. Raval, Karimuddin and Phang for assistance with patient recruitment.

Contributors MM, MTVC, DaC, JS, DoC, CVW, DT, GM, RDS, CB, AS, WA, RA, AAD, EES, MDH, MsA, MsU, ST, AM, DJS, GG, SP, IC, WKKW, SCHY, TG, PSIL, NR, YLS, TGS, EW, JK, MD, JMM, MF-VO-S, HL, SS, DS and PJ:D contributed to the design of the study, involved in drafting of the manuscript and approved the final version for publication. MM had full access to all study data and took responsibility for data integrity and the accuracy of the data analysis.

Funding This work was supported by CIHR’s Strategy for Patient-Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care; Health and Medical Research Fund (11120321), Food and Health Bureau, Hong Kong Government; Auckland District Health Board Charitable Trust; Neurological Foundation of New Zealand.

Disclaimer The views expressed are not necessarily shared with the Province of Ontario and the Ministry of Health and Long-Term Care. The study funders have no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and preparation.

Competing interests EES reports grants from McMaster University, during the conduct of the study. TG reports grants from Food and Health Bureau, HK government, during the conduct of the study. PJ:D reports grants from Abbott Diagnostics, grants from Boehringer-Ingelheim, grants from Coviidien, grants from Octapharma, grants from Philips Healthcare, grants from Roche Diagnostics, grants from Stryker, outside the submitted work. DoC reports grants from Neurological Foundation of New Zealand, during the conduct of the study. MDH reports personal fees from Merck, non-financial support from Hoffmann-La Roche Canada, grants from Covidiend Medtronic), grants from Boehringer-Ingelheim, grants from Stryke, grants from Medtronic, outside the submitted work. In addition, MDH has a patent Systems and Methods for Assisting in Decision-Making and Triaging for Acute Stroke Patients pending to US Patent office Number: 62/086,077 and owns stock in Calgary Scientific, a company that focuses on medical imaging software, is a director of the Canadian Federation of Neurological Sciences, a not-for-profit group and has received grant support from Alberta Innovates Health Solutions, CIHR, Heart and Stroke Foundation of Canada, National Institutes of Neurological Disorders and Stroke. MTVC reports grants from Health and Medical Research Fund (11120321), Food and Health Bureau, Hong Kong government during the conduct of the study. TGS reports grants from New Zealand Neurological Foundation during the conduct of the study.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet 2008;372:139–44.
2. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–47.
3. Larsen SF, Zarić D, Boysen G. Postoperative cerebrovascular accidents in general surgery. Acta Anaesthesiol Scand 1988;32:698–701.
4. Popa AS, Rabinstein AA, Huddleston PM, et al. Predictors of ischemic stroke after hip operation: a population-based study. J Hosp Med 2009;4:298–303.

5. Turnipseed WD, Berkoff HA, Belzer FO. Postoperative stroke in cardiac and peripheral vascular disease. Ann Surg 1980;192:365–8.
6. Matthey P, Finucane BT, Finegan BA. The attitude of the general public towards preoperative assessment and risks associated with general anaesthesia. Can J Anaesth 2001;48:333–8.
7. Huckle W, Donnan GA, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–74.
8. Debette S, Beiser A, DeCarli C, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 2010;41:600–6.
9. Longstreth WT, Dulberg C, Manolio TA, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002;33:2379–82.
10. Lövblad KO, Piuschke W, Remonda L, et al. Diffusion-weighted MRI for monitoring neurovascular interventions. Neuroradiology 2000;42:134–8.
11. Vermeer SE, Prins ND, den Heijer T, et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–22.
12. Longstreth WT, Bernick C, Manolio TA, et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217–25.
13. Hachinski V, et al.Stroke 2006;37:2220–41.
14. Pendlebury ST, Marjir, Bull L, et al. MoCA, ACE-R, and MMSE versus the National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards Neuropsychological Battery after TIA and stroke. Stroke 2012;43:464–9.
15. Dong Y, Sharma VK, Khan BP, et al. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci 2010;299:15–18.
16. Godfrey R, Fickl A, Roussel M, et al. Is the Montreal cognitive assessment superior to the mini-mental state examination to detect poststroke cognitive impairment? A study with neuropsychological evaluation. Stroke 2011;42:1712–6.
17. Pendlebury ST, Cuthbertson FC, Welch SJ, et al. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke 2010;41:1290–3.
18. Wong A, Xiong YY, Kwan PW, et al. The validity, reliability and clinical utility of the Hong Kong Montreal Cognitive Assessment (HK-MoCA) in patients with cerebral small vessel disease. Dement Geriatr Cogn Disord 2009;28:81–7.
19. Borland E, Nägga K, Nilsson PM, et al. The Montreal cognitive assessment: normative data from a large swedish population-based cohort. J Alzheimers Dis 2017;59:893–901.
20. Rossetti HC, Lacritz LH, Cullum CM, et al. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011;77:1272–5.
21. Santangelo G, Siciliano M, Pedone R, et al. Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 2015;36:585–91.
22. Baracchini C, Mazzalai F, Gruppo M, et al. Carotid endarterectomy protects elderly patients from cognitive decline: a prospective study. Surgery 2012;151:99–106.
23. Mrkobrada M, Hill MD, Chan MT, et al. Covert stroke after non-cardiac surgery: a prospective cohort study. Br J Anaesth 2016;117:191–7.
24. Salthouse TA. The role of memory in the age decline in digit-symbol substitution performance. J Gerontol 1978;33:232–8.
25. Tombaugh TN. Trail Making Test A and B: normative data stratified by age. Arch Neuropsychol 2004;19:203–14.
26. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969:9:179–86.
27. Rankin J. Cerebral vascular accidents in patients over the age of 60. I. General considerations. Scott Med J 1957;2:127–36.
28. Hoyt WT, Alessi CA, Harker JO, et al. Development and testing of a five-item version of the Geriatric Depression Scale. J Am Geriatr Soc 1999;47:873–8.
29. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
30. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990;113:941–8.
31. Devereaux PJ, Chan MT, Alonso-Coello P, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. *JAMA* 2012;307:2295–304.
32. Barber PA, Hach S, Tippett LJ, et al. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. *Stroke* 2008;39:1427–33.
33. Bendszus M, Reents W, Franke D, et al. Brain damage after coronary artery bypass grafting. *Arch Neurol* 2002;59:1090–5.
34. Cook DJ, Huston J, Treanor MR, et al. Postcardiac surgical cognitive impairment in the aged using diffusion-weighted magnetic resonance imaging. *Ann Thorac Surg* 2007;83:1389–95.
35. Warach S, Gaa J, Siewert B, et al. Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. *Ann Neurol* 1995;37:231–41.
36. Wardlaw JM, Smith EE, Bissels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013;12:822–38.
37. Canadian Institutes of Health Research, N.S.a.E.R.C.o.C., and Social Sciences, Humanities Research Council of Canada. Tri-Council policy statement: ethical conduct for research involving humans, 2014.
38. Wardlaw JM, Davies H, Booth TC, et al. Acting on incidental findings in research imaging. *BMJ* 2015;351:h5190.
39. Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. *Lancet* 1998;351:857–61.
40. Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive dysfunction after major noncardiac surgery. *Anesthesiology* 2008;108:18–30.
41. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2010;341:c3666.
42. Wax Y. Collinearity diagnosis for a relative risk regression analysis: an application to assessment of diet-cancer relationship in epidemiological studies. *Stat Med* 1992;11:1273–87.
43. Simes RJ, Greatorex V, Gebski VJ. Practical approaches to minimize problems with missing quality of life data. *Stat Med* 1998;17:725–37.
44. Curran D, Bacchi M, Schmitz SF, et al. Identifying the types of missingness in quality of life data from clinical trials. *Stat Med* 1998;17:739–56.